Additional file 1 of Upadacitinib effectiveness and factors associated with minimal disease activity achievement in patients with psoriatic arthritis: preliminary data of a real-life multicenter study

Additional file 1: Additional Table 1a. Characteristics of the UPREAL-PsA study patients subgroups at baseline. Additional Table 1b. Characteristics of the UPREAL-PsA study patients subgroups at baseline. Additional Table 2. List of the comorbidities considered as Other in patients of the UPREAL-PsA study. Additional Table 3. List of the previous bDMARDs used in bio-failure patients. Additional Table 4. DAPSA responses in patients’ subgroups of the UPREAL-PsA study. Additional Table 5. ASDAS-CRP responses in patients’ subgroups of the UPREAL-PsA study. Additional Table 6. List of all the adverse events observed in patients of the UPREAL-PsA study